MX2018004361A - Nuevos compuestos para el tratamiento de la fibrosis quistica. - Google Patents
Nuevos compuestos para el tratamiento de la fibrosis quistica.Info
- Publication number
- MX2018004361A MX2018004361A MX2018004361A MX2018004361A MX2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A
- Authority
- MX
- Mexico
- Prior art keywords
- cystic fibrosis
- treatment
- novel compounds
- cftr
- stabilizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/382—Cystic fibrosis
Abstract
Un agente corrector capaz de estabilizar una proteína reguladora de la conductancia transmembrana en la fibrosis quística (CFTR) recién sintetizada, útil en el tratamiento de la fibrosis quística.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562239699P | 2015-10-09 | 2015-10-09 | |
PCT/IB2016/056035 WO2017060879A1 (en) | 2015-10-09 | 2016-10-07 | Novel compounds for treatment of cystic fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018004361A true MX2018004361A (es) | 2018-09-18 |
Family
ID=57200058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004361A MX2018004361A (es) | 2015-10-09 | 2016-10-07 | Nuevos compuestos para el tratamiento de la fibrosis quistica. |
Country Status (9)
Country | Link |
---|---|
US (1) | US10130622B2 (es) |
EP (1) | EP3359540A1 (es) |
JP (1) | JP2018529707A (es) |
CN (1) | CN108602816A (es) |
AU (1) | AU2016333907A1 (es) |
BR (1) | BR112018007165A2 (es) |
CA (1) | CA3000802A1 (es) |
MX (1) | MX2018004361A (es) |
WO (1) | WO2017060879A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3212189T1 (sl) * | 2014-10-31 | 2020-11-30 | Abbvie Overseas S.A R.L. | Substituirani kromani in postopki uporabe |
ES2829636T3 (es) * | 2015-10-09 | 2021-06-01 | Abbvie Overseas Sarl | Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso |
GB201905711D0 (en) * | 2019-04-24 | 2019-06-05 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
LT2489659T (lt) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Atp rišančios kasetės transporterių moduliatoriai |
US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
AU2008256717B2 (en) | 2007-05-25 | 2013-11-21 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
JP5455922B2 (ja) | 2007-12-10 | 2014-03-26 | ノバルティス アーゲー | 有機化合物 |
JP5637859B2 (ja) | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
DK2358680T3 (da) | 2008-10-23 | 2013-06-24 | Vertex Pharma | Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2012048181A1 (en) | 2010-10-08 | 2012-04-12 | N30 Pharmaceuticals, Llc | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013043720A1 (en) | 2011-09-20 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by plunc proteins |
AU2013348018A1 (en) * | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
MX368263B (es) | 2013-05-07 | 2019-09-26 | Galapagos Nv | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. |
SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
CA2942387A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr actvity |
US9790219B2 (en) | 2014-03-13 | 2017-10-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
AU2015339196A1 (en) | 2014-10-31 | 2017-05-11 | Abbvie S.A.R.L. | Substituted tetrahydropyrans and method of use |
SI3212189T1 (sl) | 2014-10-31 | 2020-11-30 | Abbvie Overseas S.A R.L. | Substituirani kromani in postopki uporabe |
-
2016
- 2016-10-07 AU AU2016333907A patent/AU2016333907A1/en not_active Abandoned
- 2016-10-07 EP EP16785568.3A patent/EP3359540A1/en not_active Withdrawn
- 2016-10-07 JP JP2018516047A patent/JP2018529707A/ja active Pending
- 2016-10-07 MX MX2018004361A patent/MX2018004361A/es unknown
- 2016-10-07 BR BR112018007165A patent/BR112018007165A2/pt not_active Application Discontinuation
- 2016-10-07 WO PCT/IB2016/056035 patent/WO2017060879A1/en active Application Filing
- 2016-10-07 US US15/288,400 patent/US10130622B2/en not_active Expired - Fee Related
- 2016-10-07 CA CA3000802A patent/CA3000802A1/en not_active Abandoned
- 2016-10-07 CN CN201680072404.9A patent/CN108602816A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
US10130622B2 (en) | 2018-11-20 |
CA3000802A1 (en) | 2017-04-13 |
BR112018007165A2 (pt) | 2019-01-22 |
JP2018529707A (ja) | 2018-10-11 |
AU2016333907A1 (en) | 2018-04-12 |
WO2017060879A1 (en) | 2017-04-13 |
US20170100386A1 (en) | 2017-04-13 |
CN108602816A (zh) | 2018-09-28 |
EP3359540A1 (en) | 2018-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277491A (en) | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator | |
MX2018004361A (es) | Nuevos compuestos para el tratamiento de la fibrosis quistica. | |
ZA201902124B (en) | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | |
AU2015328174A8 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
MX2020005753A (es) | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. | |
MX2021013638A (es) | Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quistica. | |
AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
MX2019010155A (es) | Arnm de cftr optimizado por codón novedoso. | |
EP3099784A4 (en) | Improved carbon dioxide fixation via bypassing feedback regulation | |
MX2018003678A (es) | Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion. | |
EP3368580A4 (en) | ALTERNATIVE POST-TREATMENT OF STABILIZATION OF HIGHLY DISORDERED CELLULOSES | |
EP3254704A4 (en) | Hydrogen peroxide solution supply apparatus | |
EP3615084A4 (en) | MEMBRANE-ACTIVE MOLECULES | |
EP3634489A4 (en) | IMPROVED METHODS FOR GENERATING SMALL MOLECULAR DEGRADERS AND DIMERIZERS | |
EP3500325A4 (en) | PORTABLE SPRAYER | |
MY174200A (en) | Process for reducing the chlorine content of organotetraphosphites | |
EP3604293A4 (en) | METHOD FOR STABILIZING A HIGHLY PURE ETHYLENE CARBON COMPOSITION | |
EP3448369A4 (en) | COMPOUNDS AND COMPOSITIONS FOR TREATING THE METABOLISM SYNDROME AND METHOD THEREFOR | |
EP3279660A4 (en) | Preservative solution for heme protein, and method for stabilizing heme protein | |
EP3646849A4 (en) | SINGULET OXYGEN TRAP | |
EP3435995A4 (en) | METHOD FOR THE TREATMENT OF METABOLISM TROUBLES | |
MX2017010899A (es) | Proceso para la preparacion de triazoles. | |
AU2016903020A0 (en) | Treatment for fibrosis | |
AU2015905412A0 (en) | Quality Integral regulator Software Development Project (VENQIR) | |
PL3153022T3 (pl) | N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid |